Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
FDA Orphan Drug Designation
Sort By
Newest First
1 / 1
1 / 1
FDA
BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma
BioInvent
PR-M01-19-NI-088
Jan 30, 2019
Drug Designation
Martin Pharmaceuticals’ LIVANTRA™ Receives FDA Orphan Drug Designation in Second Indication
Martin Pharmaceuticals
PR-M09-18-NI-033
Sep 13, 2018
FDA Orphan Drug Designation
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
Pliant Therapeutics
PR-M08-18-NI-058
Aug 15, 2018
Orphan Drug
Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)
Processa Pharmaceuticals, Inc.
PR-M06-18-NI-079
Jun 25, 2018
Orphan Drug
Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis
Samus Therapeutics
PR-M06-18-NI-050
Jun 14, 2018
Drug Designation
Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Genea Biocells
PR-M06-18-NI-016
Jun 06, 2018
